2018 Biomedtracker Datamonitor Healthcare Post-ASH Report
2018 Biomedtracker Datamonitor Healthcare Post-ASH Report
$599.00
The 60th American Society of Hematology (ASH) Annual Meeting and Exposition was held in San Diego, CA from December 1-4, 2018.
Publisher: Biomedtracker / Meddevicetracker / Datamonitor Healthcare
- Description
- Contents
Overview
The 60th American Society of Hematology (ASH) Annual Meeting and Exposition was held in San Diego, CA from December 1-4, 2018. This post-meeting report features commentary from our analysts on specific presentations across multiple indications as well as an introduction highlighting developments in acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and multiple myeloma. It also includes a compilation of all data events added in conjunction with the meeting.
TABLE OF CONTENTS
Selected Abstracts Featured at ASH………………………………………………………………………………………………13
Acute Lymphocytic Leukemia (ALL)……………………………………………………………………………………………13
Selinexor (KPTI, Phase I) ……………………………………………………………………………………………………….13
AFM11 (AFMD, Phase I)………………………………………………………………………………………………………..14
AUTO3 (Autolus, Phase II) …………………………………………………………………………………………………….16
Yescarta (GILD, Phase II)……………………………………………………………………………………………………….18
Acute Myelogenous Leukemia (AML)…………………………………………………………………………………………20
Indoximod (NLNK, Phase II) …………………………………………………………………………………………………..20
Xospata (Astellas, Approved)…………………………………………………………………………………………………22
AMG 330 (AMGN, Phase I) ……………………………………………………………………………………………………24
Idhifa (CELG, Approved) ……………………………………………………………………………………………………….26
Tibsovo (AGIO, Approved)…………………………………………………………………………………………………….28
Quizartinib (Daiichi Sankyo, NDA)…………………………………………………………………………………………..30
Anemia ………………………………………………………………………………………………………………………………….32
Monofer (Helsinn, Phase III)………………………………………………………………………………………………….32
Bone Marrow Transplant and Stem Cell Transplant……………………………………………………………………..35
Iomab-B (ATNM, Phase III) ……………………………………………………………………………………………………35
Rivo-cel (BLCM, Phase II)………………………………………………………………………………………………………37
Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) – NHL ………………………39
Lisocabtagene Maraleucel (CELG, Phase II)……………………………………………………………………………..39
Imbruvica (ABBV, Approved) …………………………………………………………………………………………………40
Imbruvica (ABBV, Approved) …………………………………………………………………………………………………42
CTL119 (NVS, Phase I)…………………………………………………………………………………………………………..44
Calquence (AZN, Phase III)…………………………………………………………………………………………………….46
Chronic Myelogenous Leukemia (CML)………………………………………………………………………………………49
Sprycel (BMY, Approved)………………………………………………………………………………………………………49
Cutaneous T-Cell Lymphoma (CTCL) – NHL………………………………………………………………………………….50
Copiktra (VSTM, Phase I) ………………………………………………………………………………………………………50
Diffuse Large B-Cell Lymphoma (DLBCL) – NHL…………………………………………………………………………….53
Selinexor (KPTI, Phase II) ………………………………………………………………………………………………………53
Polatuzumab (Roche, Phase III) ……………………………………………………………………………………………..55
AUTO3 (Autolus, Phase II) …………………………………………………………………………………………………….57
RG6026 (Roche, Phase I) ………………………………………………………………………………………………………58
December 2018 / 11
2018 Post-ASH Report
TG-1303 (TGTX, Phase III)……………………………………………………………………………………………………..60
Adcetris (SGEN, Phase II) ………………………………………………………………………………………………………62
MOR208 (MOR, Phase III)……………………………………………………………………………………………………..64
Hematologic Cancer………………………………………………………………………………………………………………..66
JCAR014 (CELG, Investigator Initiated)……………………………………………………………………………………66
Immune Thrombocytopenic Purpura (ITP)………………………………………………………………………………….67
Efgartigimod (ARGX, Phase II)………………………………………………………………………………………………..67
Indolent Non-Hodgkin’s Lymphoma (Including Follicular Lymphoma) – NHL ……………………………………71
Revlimid (CELG, Phase III)……………………………………………………………………………………………………..71
Mantle Cell Lymphoma – NHL……………………………………………………………………………………………………73
Zanubrutinib (BGNE, Phase II) ……………………………………………………………………………………………….73
Multiple Myeloma (MM)………………………………………………………………………………………………………….75
bb21217 (CELG, Phase I) ………………………………………………………………………………………………………75
Darzalex (JNJ, Approved)………………………………………………………………………………………………………77
LCAR-B38M (JNJ, Phase II)…………………………………………………………………………………………………….78
MOR202 (MOR, Development Outside U.S.)……………………………………………………………………………80
Ninlaro (TAK, Approved)……………………………………………………………………………………………………….82
Darzalex (JNJ, Approved)………………………………………………………………………………………………………84
AMG 420 (AMGN, Phase I) ……………………………………………………………………………………………………86
Empliciti (BMY, Approved)…………………………………………………………………………………………………….88
Myelodysplastic Syndrome (MDS)……………………………………………………………………………………………..90
Luspatercept (XLRN, Phase III)……………………………………………………………………………………………….90
Non-Hodgkin’s Lymphoma (NHL) ………………………………………………………………………………………………92
RG6026 (Roche, Phase I) ………………………………………………………………………………………………………92
Peripheral T-Cell Lymphoma (PTCL) – NHL…………………………………………………………………………………..94
Tipifarnib (Oncology) (KURA, Phase II)…………………………………………………………………………………….94
Copiktra (VSTM, Phase II) ……………………………………………………………………………………………………..96
Sickle Cell Anemia……………………………………………………………………………………………………………………98
Voxelotor (GBT, Phase III)……………………………………………………………………………………………………..98
BCL11a shRNA(miR) (BLUE, Phase I)……………………………………………………………………………………..102
RVT-1801 (Roivant, Phase II) ……………………………………………………………………………………………….103
LentiGlobin (BLUE, Phase I) …………………………………………………………………………………………………105
Thalassemia………………………………………………………………………………………………………………………….106
LentiGlobin (BLUE, Phase III) ……………………………………………………………………………………………….106
Luspatercept (XLRN, Phase III)……………………………………………………………………………………………..113
LentiGlobin (BLUE, Phase III) ……………………………………………………………………………………………….115
LentiGlobin (BLUE, Phase III) ……………………………………………………………………………………………….117
List of Biomedtracker ASH Events ………………………………………………………………………………………………120
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Brexit At The 11th Hour: UK Refreshes No-Deal Guidance For Medtech 
Sign up to the